Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Neogenomics Inc (NEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,028,738
  • Shares Outstanding, K 95,470
  • Annual Sales, $ 276,740 K
  • Annual Income, $ 2,640 K
  • 60-Month Beta 0.91
  • Price/Sales 7.29
  • Price/Cash Flow 65.29
  • Price/Book 6.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.04
  • Number of Estimates 4
  • High Estimate 0.05
  • Low Estimate 0.02
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.50 +8.97%
on 04/30/19
23.85 -10.90%
on 05/06/19
+1.27 (+6.36%)
since 04/24/19
3-Month
18.00 +18.06%
on 03/07/19
23.85 -10.90%
on 05/06/19
+2.27 (+11.96%)
since 02/22/19
52-Week
11.05 +92.31%
on 12/24/18
23.85 -10.90%
on 05/06/19
+9.68 (+83.66%)
since 05/24/18

Most Recent Stories

More News
NeoGenomics To Attend The 16th Annual Craig-Hallum Institutional Investor Conference

FT. MYERS, FL / ACCESWIRE / May 23, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chief Executive Officer, Sharon...

NEO : 21.25 (+0.62%)
NeoGenomics Announces Proposed Public Offering of Common Stock

FT. MYERS, FL / ACCESSWIRE / May 20, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has commenced an underwritten public...

MS : 42.96 (+0.59%)
NEO : 21.25 (+0.62%)
Nanostring Techn has the Best Relative Performance in the Life Sciences Tools & Services Industry (NSTG , FLDM , NEO , A , TMO )

Here are the top 5 stocks in the Life Sciences Tools & Services industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were...

NEO : 21.25 (+0.62%)
NSTG : 27.76 (+3.35%)
FLDM : 12.08 (-0.82%)
Nanostring Techn is Among the Companies in the Life Sciences Tools & Services Industry with the Best Relative Performance (NSTG , NEO , BRKR , QGEN , PACB )

Here are the top 5 stocks in the Life Sciences Tools & Services industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were...

BRKR : 42.31 (+0.52%)
NEO : 21.25 (+0.62%)
NSTG : 27.76 (+3.35%)
Neogenomics Inc is Among the Companies in the Life Sciences Tools & Services Industry with the Best Relative Performance (NEO , PRAH , PKI , TMO , CRL )

Below are the top five companies in the Life Sciences Tools & Services industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks...

NEO : 21.25 (+0.62%)
PRAH : 89.05 (+1.52%)
PKI : 86.36 (+0.27%)
Shares of Neogenomics Inc Rank the Highest in Terms of Relative Performance in the Life Sciences Tools & Services Industry (NEO , FLDM , WAT , BRKR , PKI )

We looked at the Life Sciences Tools & Services industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength....

NEO : 21.25 (+0.62%)
WAT : 206.25 (+0.59%)
FLDM : 12.08 (-0.82%)
Shares of Neogenomics Inc Rank the Highest in Terms of Relative Performance in the Life Sciences Tools & Services Industry (NEO , CBM , PACB , TMO , ILMN )

Below are the top five companies in the Life Sciences Tools & Services industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks...

PACB : 6.80 (-1.59%)
NEO : 21.25 (+0.62%)
CBM : 41.67 (+2.06%)
NeoGenomics (NEO) Tops Q1 Earnings and Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 40.00% and 9.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

NEO : 21.25 (+0.62%)
NeoGenomics Reports 51% Revenue Growth to Record $96 Million in the First Quarter

a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2019.

NEO : 21.25 (+0.62%)
HDVY : 0.0604 (+0.67%)
Shares of Neogenomics Inc Rank the Highest in Terms of Relative Performance in the Life Sciences Tools & Services Industry (NEO , FLDM , PKI , PACB , A )

Here are the top 5 stocks in the Life Sciences Tools & Services industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were...

NEO : 21.25 (+0.62%)
FLDM : 12.08 (-0.82%)
PKI : 86.36 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade NEO with:

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Key Turning Points

2nd Resistance Point 21.90
1st Resistance Point 21.58
Last Price 21.25
1st Support Level 21.02
2nd Support Level 20.78

See More

52-Week High 23.85
Last Price 21.25
Fibonacci 61.8% 18.96
Fibonacci 50% 17.45
Fibonacci 38.2% 15.94
52-Week Low 11.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar